Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases

Summary

There is currently an urgent need for low cost and well tolerated intralesional agents for the management of in transit and cutaneous melanoma metastases that are unsuitable for, or resistant to, other therapies. This pilot study will determine whether intralesional injections of the sclerosant polidocanol into intransit and cutaneous melanoma lesions shows promise for efficacy, safety and ease of use that will enable this inexpensive and widely available agent to undergo further evaluation.

Timeline

Start

2020-05-20

Primary completion

2022-12

Completion

2022-12

Drugs

Indications